Monitoring and Management of Immunea??Related Adverse Events Associated With Programmed Cell Death Proteina??1 Axis Inhibitors in Lung Cancer

摘要

Monoclonal antibodies targeting programmed cell death proteina??1 (PDa??1) represent a new treatment paradigm in nona??small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard seconda??line chemotherapy. Nevertheless, the adverse events associated with PDa??1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immunea??related adverse events in lung cancer patients receiving these agents. Implications for Practice. The potential adverse events of immune checkpoint inhibitors differ from conventional chemotherapy and can require a multidisciplinary approach. Continued education is important for all physicians to ensure optimal care for patients.